BioRestorative Therapies (BRTX) FCF Margin (2012 - 2025)
BioRestorative Therapies' (BRTX) quarterly FCF Margin came in at 12651.37% in Q4 2025, down 720038.0% YoY from N/an in Q4 2024, and up 48.52% on a QoQ basis from 24576.27% in Q3 2025.
BioRestorative Therapies (BRTX) FCF Margin (2012 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 14 years of FCF Margin data on file, last reported at 12651.37% in Q4 2025.
- Quarterly FCF Margin fell 720038.0% year-over-year to 12651.37% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 3034.77% (down 95583.0% YoY) and the FY2025 annual result came in at 3034.77%, down 95583.0% from the prior year.
- FCF Margin climbed to 12651.37% in Q4 2025, from 24576.27% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 752.57% in Q3 2024 to a low of 44818.08% in Q4 2022.
- A 5-year average of 9461.07% and a median of 6078.39% in 2024 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin jumped 3622748 bps — and 2025, when it plunged 2382370 bps.
- Tracing BRTX's FCF Margin over 5 years: stood at 22900.28% in 2021, then sank by 96 bps to 44818.08% in 2022, then soared by 81 bps to 8590.6% in 2023, then jumped by 37 bps to 5450.99% in 2024, then sank by 132 bps to 12651.37% in 2025.
- The last three FCF Margin figures came in at 12651.37% (Q4 2025), 24576.27% (Q3 2025), and 897.2% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 | -12,651.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12,651.37% |
| Sep 30, 2025 | -24,576.27% |
| Jun 30, 2025 | -897.20% |
| Mar 31, 2025 | -11,260.74% |
| Dec 31, 2024 | -5,450.99% |
| Sep 30, 2024 | -752.57% |
| Jun 30, 2024 | -2,100.13% |
| Mar 31, 2024 | -6,705.79% |
| Dec 31, 2023 | -8,590.60% |
| Sep 30, 2023 | -3,880.67% |
| Jun 30, 2023 | -2,082.39% |
| Mar 31, 2023 | -7,695.73% |
| Dec 31, 2022 | -44,818.08% |
| Sep 30, 2022 | -4,920.87% |
| Jun 30, 2022 | -1,953.30% |
| Mar 31, 2022 | -10,651.29% |
| Dec 31, 2021 | -22,900.28% |
| Sep 30, 2021 | -7,867.05% |
| Jun 30, 2021 | -4,945.53% |
| Mar 31, 2021 | -4,520.56% |